Spirogen develop potent small molecules based on novel mechanisms and chemistry in the fight to target important cancers. We produce DNA sequence targeted agents utilizing cutting edge technologies to improve worldwide health and wellbeing.
For general enquiries please email info@spirogen.com and you will be directed to the appropriate individual to answer your queries.
Our lead cancer drug
SG2000
SG2000, a C2-unsaturated PBD dimer, in Phase II clinical trials in the USA with further trials planned in Europe. In four Phase I trials, a total of 69 patients were treated with SG2000 on various schedules. Three objective partial responses were seen in refractory ovarian carcinoma (64% decrease), ALL (84% blasts reduced to …
read more »
Our other products
SG2285
SG2285 is differentiated from SG2000 in that it is a PBD dimer C11-prodrug which is activated by hydrolysis. Its active component, SG2202, is even more potent than SG2000 and the combination of the…
read more »
AS-1-145 (Centanamycin)
Centanamycin (AS-I-145 or NSC 716970) is an indolecarboxamide synthesized by Professor Moses Lee’s group at Hope University (USA) as a less toxic achiral analog of CC-1065 and duocarmycin, a …
read more »